{"topic_id":"ade_selegiline_adverse_events","category":"ade","context":"---\ntopic_id: ade_selegiline_adverse_events\ncategory: ade\ntitle: \"FDA ADE reports for Selegiline (MAO-B inhibitor (canine cognitive dysfunction, Cushing's)) — total reports, species & reaction breakdown\"\nlang: en\nsource: \"openFDA animalandveterinary/event.json (FDA CVM adverse event reports), pulled 2026-07-22\"\nsource_file: pdf-raw/ade/ade_active_ingredients_2026-07-22_b8.json\ndate_parsed: 2026-07-22\ntokens_estimated: 192\nverification:\n  method: substring_match\n  claims: 32\n  passed: 32\n  date: 2026-07-22\n---\n\n# Selegiline — FDA Animal & Veterinary Adverse Event (ADE) Reports\n\nSource: openFDA `animalandveterinary/event.json`, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-07-22. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Selegiline is a MAO-B inhibitor (canine cognitive dysfunction, Cushing's).\n\n## Total reports\nSelegiline: 4321\n\n## Reports by species (top entries)\n- Dog 3942\n- Human 46\n- Cat 37\n- Other 2\n- Parrot 1\n\n## Top reported reactions (VEDDRA terms, top entries)\n- Vomiting 439\n- INEFFECTIVE, COGNITIVE DYSFUNC 403\n- INEFFECTIVE, LOSS OF EFFECT 333\n- Diarrhoea 324\n- Anorexia 320\n- Lack of efficacy - NOS 307\n- Depression 306\n- INEFFECTIVE, CUSHINGS 243\n- Restlessness 243\n- Death by euthanasia 240\n\n\"Lack of efficacy\" terms denote product-performance reports, not adverse reactions.\n\nSource JSON: `pdf-raw/ade/ade_active_ingredients_2026-07-22_b8.json` (openFDA animalandveterinary/event.json, pulled 2026-07-22).\n","sources":[],"tokens_estimated":265,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}